5-羟基-4-苯基-2,3-二氢-1,2-噁唑-3-酮 | 36190-14-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-羟基-4-苯基-2,3-二氢-1,2-噁唑-3-酮
• 英文名称: 4-phenyldisic acid
• 英文别名: 4-Phenylisoxazole-3,5-diol；5-hydroxy-4-phenyl-1,2-oxazol-3-one
• CAS: 36190-14-4
• 化学式: C₉H₇NO₃
• 分子量: 177.159
• InChiKey: ZMSGYVXNYROULF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-羟基-4-苯基-2,3-二氢-1,2-噁唑-3-酮 生成 5-methoxy-5,7,7-trimethyl-3-phenyl-6,7-dihydro-5H-isoxazolo[3,2-b][1,3]oxazin-2-one
  参考文献：
  名称：

  Reaction of carbonyl compounds with 3,5-dihydroxy-4-phenylisoxazole. Novel type of noncatalyzed condensation and carbon-carbon bond formation

  摘要：

  DOI：

  10.1021/jo00950a002

文献信息

• Disic acids
  作者：G. Zvilichovsky

  DOI：10.1016/0040-4020(75)87042-6

  日期：1975.1

  4-(p-Nitrophenyl)-3,5-dihydroxyisoxazole is a remarkably strong acid which possesses unique chemical reactivity towards carbonyl compounds. It has been shown that these properties are encountered in a series of related 3,5-dihydroxyisoxazole derivatives. It appears that this isoxazole system is very electron deficient, a fact that together with a neighboring group effect is responsible for the exceptional

  4-（对硝基苯基）-3,5-二羟基异恶唑是一种非常强的酸，对羰基化合物具有独特的化学反应性。已经表明，在一系列相关的3，5-二羟基异恶唑衍生物中遇到了这些性质。看来该异恶唑体系非常缺乏电子，这一事实是与邻近基团效应共同导致了优异的酸度和反应性。电子的缺乏还反映在芳族质子的去屏蔽作用上。NMR光谱的比较用作异恶唑部分的电子缺乏的标准。这类新的酸产生了各种新颖的系统。讨论了取代对苯甲醛衍生物制得的醛二铵体系可见光谱的影响。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Molecular Structure and Stability of Isoxazolium Enolates
  作者：Gury Zvilichovsky、Mordechai David

  DOI：10.3987/r-1987-04-0961

  日期：——
• Zvilichovsky, Gury, Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 465 - 470
  作者：Zvilichovsky, Gury

  DOI：——

  日期：——
• Zvilichovsky,G., Israel Journal of Chemistry, 1971, vol. 9, p. 659 - 666
  作者：Zvilichovsky,G.

  DOI：——

  日期：——